

A. DAVID PALTIEL

Legal Name: Aaron David Paltiel

Born: November 16, 1959. Montreal, Canada

Citizenship: Citizen of both the United States and Canada

Education: BA *cum laude* (Economics) McGill University, 1981
MBA, Yale University, 1985
MA, MPhil, Yale University, 1990
PhD (Operations Research) Yale University, 1992

Career:

1996 – **Yale School of Medicine**, New Haven, CT
Yale School of Management, New Haven, CT
Professor (2006 – present)
Associate Professor (1998 – 2006)
Assistant Professor (1996 – 1998)

1992 – 1996 **Harvard School of Public Health**, Boston, MA
John F. Kennedy School of Government, Cambridge, MA
Assistant Professor

1990 **The RAND Corporation**, Santa Monica, CA
Contract Consultant

1985 – 1987 **Booz, Allen & Hamilton, Inc.**, New York, NY
Associate

Service: National/International Panels

- 2023 - **ANRS | Emerging Infectious Diseases** French National Agency for Research on AIDS and Emerging ID. Priority Research and Equipment Programme.
Member, Scientific Evaluation Committee.
- 2016 - 2017 **National Academy of Medicine**
Member, Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse.
- 2009 - 2014 **Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS)** French National Agency for Research on AIDS and Viral Hepatitis.
Member, Scientific Advisory Committee, Research in Developing Countries.
- 2010 - 2012 **International Society for Pharmacoeconomics & Outcomes Research (ISPOR) and Society for Medical Decision Making (SMDM)**
Member, Leadership Group, Modeling Good Research Practices Task Force.
- 2008 - 2009 **Institute of Medicine (National Academy of Medicine)**
Member, Committee on Review of Priorities in the National Vaccine Plan. (Mandated by the US Department of Health and Human Services to review and make recommendations regarding an update of the National Vaccine Plan.)
- 2006 - 2008 **United States Preventive Services Task Force**
Expert Reviewer, Updated Recommendations on HIV Screening.
- 2006 - 2007 **Institute of Medicine (National Academy of Medicine)**
Member, Committee on the Role of Community-Based Mitigation Strategies During an Influenza Pandemic. (Mandated by the Dept. of Health and Human Services to assess the technical merit and applicability of disease models as a guide to containment policy.)
- 2006 - 2009 **Institut de Veille Sanitaire** (French national equivalent of US CDC)
Consultant, Development of National Recommendations for HIV Screening.
- 2005 -2007 **Institute of Medicine (National Academy of Medicine)**
Member, Committee on the President's Emergency Plan for AIDS Relief [PEPFAR] Implementation Evaluation. (Mandated by the US Congress to report on the \$15 billion PEPFAR program in preventing and treating HIV/AIDS in the developing world.)
- 2005 - 2008 **National Institutes of Health**
Member, Study Section BSPH (Behavioral and Social Science Approaches to Preventing HIV/AIDS). Three-year term.
- 2005 - 2006 **United States Centers for Disease Control and Prevention**
Consultant, Revised Recommendations for HIV Screening of Adults, Adolescents and Pregnant Women in Health Care Settings.

2002 - 2004 **Institute of Medicine (National Academy of Medicine)**
Member, Committee on the Ryan White CARE Act: Data for Resource Allocation, Planning and Evaluation.

Service: Editorial Boards

1999 - 2005 **Value in Health**
Co-Editor (one of a panel of six)

Value in Health is the journal of the International Society for Pharmacoeconomics and Outcomes Research. As one of six founding Editors, I guided the journal from its first issue, through its inclusion in Medline, to its attainment of the #1 Impact Factor ranking in both the “Health Care Sciences & Services” science category and the “Health Policy and Services” social science category.

1998 - 2001 **Medical Decision Making**
Member, Editorial Board

Service: Leadership in Professional and Scholarly Organizations (since 2008)

2016-2017 **9th International AIDS Society Conference (Paris, 2017)**
Member, Implementation Science Track Committee

2012 - **Bocconi University**, Milan, Italy
External Member, Committee on Appointments and Promotions
Member, Scientific Advisory Board, CERGIS: Centre for Research on Health and Social Care Management (2012-2018)

2010 - **University of Pittsburgh, School of Public Health**, Pittsburgh, PA
Department of Health Policy and Management
Member, National Advisory Committee

2008 - **Stanford University**, Stanford, CA
Center for Health Policy / Center for Primary Care & Outcomes Research
Adjunct Associate

2000 - 2017 **Society for Medical Decision Making**
Chair, Finance Committee (2012 – 2017)
Secretary-Treasurer (Elected, 2008 – 2009)
Trustee (Elected, 2000 – 2002)

Honors

Connecticut Academy of Science and Engineering
Member, Elected February 2014

Active Grants

1R01HD111355 (Neilan)

09/01/2020 – 07/31/2025

NIH/NICHD

Adolescent-tailored HIV treatment and prevention strategies in South Africa: projecting clinical benefits and value

Goals: New model structure development to permit adolescent-specific age and time-varying clinical parameters and interventions, including novel prevention and treatment medication formulations, for projecting the clinical and economic outcomes related to HIV treatment and prevention strategies among adolescent men in South Africa.

Role: Investigator/Subaward PI

1R01DA050482-01 (Reddy)

09/01/2020 – 07/31/2025

NIH/NIDA

Tobacco Use and Cessation, HIV, and TB in South Africa: Clinical and Economic Outcomes

Goals: This project will combine an integrated cost-effectiveness model of tobacco, HIV, and tuberculosis care with tobacco-related findings from a population-based cohort in South Africa to project clinical and economic outcomes and cost-effectiveness of tobacco cessation interventions in HIV care.

Role: Investigator/Subaward PI

5R37DA15612-18 (Owens)

09/25/2002 – 11/30/2028

Stanford University (Prime – NIH/NIDA)

Making Better Decisions: Policy Modeling for AIDS & Drug Abuse

Goals: Develop and apply mathematical policy modeling techniques to the evaluation of AIDS-related public health interventions.

Role: Investigator/Subaward PI

4R01AI093269-10 (Reddy)

09/01/2011 – 08/31/2025

NIH/NIAID

Novel Methods to Inform HIV/TB Clinical Trial Development

Goals: Apply a mathematical simulation modeling framework, based on the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) Model, to the NIAID/ACTG clinical trials infrastructure.

We propose to inform the development, design, and assessment of therapeutic, diagnostic, and 'strategy' clinical trials in HIV/TB care in international settings. The ultimate goal of this project is to apply novel scientific methods in a highly innovative fashion, to maximize trial investments. It will develop new scientific knowledge of value to HIV/TB investigators, as well as clinical trialists in many areas of medicine

Role: Investigator/Subaward PI

NU38PS004651 (Salomon)

09/30/2014 – 09/29/2025

Stanford University (Prime – CDC)

Prevention Policy Modeling Lab (NEEMA 2)

Goals: The goal of this project is to conduct health and economic modeling to inform decision-making on HIV, hepatitis, STD, TB and school health at national, state and local levels, in partnership with the National Center for HIV/AIDS Viral Hepatitis, STD and TB Prevention.

Role: Investigator

Selected Lectures

Napkin Math: Developing Model Intuition in the Digital Age. Short Course, Society for Medical Decision Making, April 26, 2023.

Policy Models to Inform COVID Screening and Prevention Decisions. Presented to Biology Department, Hamilton College, September 30, 2022.

A new drug for HIV PrEP: How much is “better” worth? Presented to Program on Regulation, Therapeutics and Law (PORTAL), Harvard Medical School (October 29, 2020).

A decision analyst's approach to assessing SARS-CoV-2 testing strategies. Presented to Population Health Research Seminar, Department of Population Health, NYU Langone Health, (October 21, 2020).

COVID-19 and higher education: What is the test we need to open college campuses? Presented to MassCPR Diagnostics Working Group, Broad Institute (June 11, 2020); Hebrew University MASHAV Global COVID-19 Forum (July 19, 2020); Columbia University COVID-19 Virtual Symposium (August 26, 2020); Harvard Medical School, COVID-19 Webinar Series (September 10, 2020); and COVID Task Forces at the following universities: Harvard/Tufts/Wellesley/Boston U/WPI (May 27, 2020); USC (June 26, 2020); Wesleyan (July 7, 2020); Yale (July 17, 2020); Lewis & Clark (August 14, 2020).

Performance de la recherche française sur le VIH: une perspective internationale. Plenary presentation at Recherche sur le VIH/SIDA et les hépatites virales: quels nouveaux enjeux? International conference organized by ANRS (French National Agency for HIV/AIDS Research. Paris (November 25, 2019).

A New Drug for HIV PrEP: How Much is “Better” Worth? Program on Regulation, Therapeutics and Law (PORTAL), Brigham & Women's Hospital, Harvard Medical School (October 29, 2020).

Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Statistical and Mathematical Modeling in Biological Applications (SaMMBA) Seminar, Institut Pasteur, Paris France (November 14, 2017). Also presented at: Department of Economics Seminar, SciencesPo, Paris France (December 8, 2017) and Department of Policy Analysis and Public Management, Bocconi University (March 27, 2018).

Coût-efficacité des soins VIH: Comment comprendre la notion de valeur dans un monde aux ressources limitées? CEPED Seminar, Université Paris Descartes (November 16, 2017). Also presented at: Ecole des Mines (Mines Paris Tech) (November 15, 2017); ISPED – Université de Bordeaux (November 9, 2017); and Séminaire Unité 1027, Université Toulouse III (October 24, 2017).

Reducing Sexual Violence by Increasing the Supply of Toilets in Khayelitsha, South Africa. Health Economics Workshop, Center for Health and Social Sciences (CHeSS), University of Chicago, (May 28, 2015). Also presented at the Toronto Health Economics and Technology Assessment Collaborative (THETA) Rounds, University of Toronto (April 10, 2015) and the Center for Health Policy/Center for Primary Care and Outcomes Research, Stanford University (March 5, 2014).

Coût-efficacité des soins VIH: Comment comprendre la notion de valeur dans un monde aux ressources limitées? Invited plenary presentation, 2014 Conférence Internationale Francophone sur le VIH et les hépatites (AFRAVIH), Montpellier, France (April 30, 2014).

Cost-Effectiveness of HIV Care: Understanding Value in a World of Limited Resources. Chennai ART (CART) Invited plenary presentation, 2013 Symposium, organized by YRGCARE Medical Centre, Chennai, India (February 10, 2013).

Economic Evaluation of Pre-Exposure Prophylaxis for HIV Infection. School of Social Service Administration, University of Chicago, Chicago, IL (March 7, 2012).

Cout efficacité des stratégies utilisant la charge virale. Invited plenary presentation, 2012 Journées scientifiques du PAC-CI, Abidjan, Côte d'Ivoire (February 16, 2012).

Cost Effectiveness of HIV Prevention and Clinical Strategies. Course faculty for “Improving the Management of HIV Disease – An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management”, sponsored by International Antivirals Society-USA. New York, NY (April 5, 2011).

Economic Evaluation of Pre-Exposure Prophylaxis for HIV Infection. School of Public Health, Hebrew University, Jerusalem, Israel (March 7, 2011).

Price, Performance and the FDA Approval Process. Institute for Technology Assessment, Massachusetts General Hospital, Boston MA (March 2, 2010).

Cost-Effectiveness in Health and Medicine. One-day workshop program prepared for National Health Service, London, United Kingdom. (November, 2009).


Policy Modeling for HIV Prevention, Screening, and Care. Interdisciplinary Seminar Series in the Life Sciences, Lafayette College, Easton PA (February, 2009).

Coût-efficacité des stratégies de dépistage du VIH. Invited presentation to the Haute Autorité de Santé (Ministry of Health), Paris, France, (June 2008).

Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. Health Economics Research Centre, University of Oxford, Oxford, UK (May 2008).

Model-based cost-effectiveness analysis in diagnostic screening. Harvard University, Children's Hospital, Boston, MA. (March 2008).

Bibliography: Peer-reviewed original research



Source: Google Scholar (August 22, 2023)

1. **Paltiel AD** and Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. *Journal of Acquired Immune Deficiency Syndromes* (1991) 4:795-804.
2. **Paltiel AD** and Kaplan EH: The epidemiological and economic consequences of AIDS clinical trials. *Journal of Acquired Immune Deficiency Syndromes* (1993) 6:179-190.
3. Stinnett AA and **Paltiel AD**. Mathematical programming techniques for resource allocation. *Journal of Health Economics* (1996) 15:641-653.
4. Neumann PJ, Zinner DE, and **Paltiel AD**. The FDA's oversight of pharmacoeconomic analysis. *Health Affairs* (1996) 15:54-71.
5. Villari P, Fattore G, Siegel JE, **Paltiel AD**, and Weinstein MC. Economic evaluation of HIV testing among intravenous drug users: analytic framework and its application to Italy. *International Journal of Technology Assessment in Health Care* (1996) 12:336-357.
6. **Paltiel AD** and Stinnett AA. Making health policy decisions: Is human instinct rational? Is rational choice human? *Chance* (1996) 9:34-39.
7. Chertow GM, **Paltiel AD**, Owen WF, and Lazarus JM. Cost-effectiveness of cancer screening in end-stage renal disease. *Archives of Internal Medicine* (1996) 156:1345-1350.
8. **Paltiel AD** and Kaplan EH. The cost-effectiveness of HIV testing: accounting for differential participation rates. *Medical Decision Making* (1997) 17:499-495.

9. Stinnett AA and **Paltiel AD**. Estimating cost-effectiveness ratios under second-order uncertainty: the mean ratio or the ratio of means. *Medical Decision Making* (1997) 17:483-489.
10. Alpher JA, **Paltiel AD**, and Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary fungal infections in AIDS patients. *Medical Decision Making* (1997) 17:373-381.
11. **Paltiel AD** and Neumann PJ. Why training is the key to successful guideline implementation. *Pharmacoeconomics* (1997) 12:297-302.
12. Freedberg KA and **Paltiel AD**. Cost-effectiveness of prophylaxis for opportunistic infections in AIDS: An overview and methodologic discussion. *Pharmacoeconomics* (1998) 14:165-174.
13. **Paltiel AD** and Freedberg KA. The cost-effectiveness of preventing Cytomegalovirus disease in AIDS patients. *Interfaces* (1998) 28(3):34-51.
14. Paltiel HJ, Connolly LP, Atala A, **Paltiel AD**, Zurakowski D, and Treves ST. The acute pediatric scrotum with indeterminate clinical presentation: Comparison of color Doppler sonography and scintigraphy. *Radiology* (1998) 207:223-231.
15. Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, and **Paltiel AD**. The cost-effectiveness of preventing AIDS-related opportunistic infections. *JAMA* (1998) 279: 130-136. 81.
16. **Paltiel AD**, Scharfstein JA, Weinstein MC, Seage GR, Losina E, Goldie SJ, Craven DE, and Freedberg KA. A Monte Carlo simulation of advanced HIV disease: application to CMV prevention. *Medical Decision Making* (1998) 18:S93-S105.
17. Kitch B, Fuhlbrigge A, Kuntz KM, Neumann P, **Paltiel AD**, Rijcken B, Schouten B, Postma DS, Weiss ST. Relationship between FEV1 and subsequent asthma attacks. *American Journal of Respiratory and Critical Care Medicine* (1999) 159:135-139.
18. Scharfstein JA, **Paltiel AD**, Weinstein MC, Seage GR, Losina E, Craven DE, and Freedberg KA. The cost-effectiveness of prophylaxis for *Mycobacterium avium* complex in AIDS. *International Journal of Technology Assessment in Health Care* (1999) 15:531-547.
19. Troche CJ, **Paltiel AD**, Makuch R. Evaluation of therapeutic strategies: A new method of balancing risk and benefit. *Value in Health* (2000) 3:12-22.
20. **Paltiel AD**. Five minutes with the Governor. *Medical Decision Making* (2000) 20:239-242.
21. **Paltiel AD**. Remarks on the role of economic modeling. *Sexually Transmitted Diseases* (2000) 27:610-616.
22. **Paltiel AD**, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, and Kuntz KM. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the Asthma Policy Model. *Journal of Allergy and Clinical Immunology* (2001) 108:39-46.
23. **Paltiel AD**, Goldie SJ, Losina E, Weinstein MC, Seage GR, Kimmel AD, Zhang H, and Freedberg KA. A pre-evaluation of clinical trial data: The case of pre-emptive CMV therapy in HIV. *Clinical Infectious Diseases* (2001) 32:783-93.

24. **Paltiel AD.** Model-based drug evaluation in chronic disease: Promise, pitfalls, and positioning. *Drug Information Journal* (2001) 35:131-139.
25. Freedberg KA, Losina E, Weinstein MC, **Paltiel AD**, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, and Goldie SJ. The cost-effectiveness of combination antiretroviral therapy in HIV. *New England Journal of Medicine* (2001) 344:824-31.
26. Yazdanpanah Y, Chêne, G, Losina E, Goldie SJ, Merchadou LD, Alfandari S, Seage GR, Sullivan L, Marimoutou C, **Paltiel AD**, Salamon R, Mouton Y, Freedberg KA. Incidence of primary opportunistic infections in two HIV-infected French clinical cohorts. *International Journal of Epidemiology* (2001) 30:864-71.
27. Fuhlbrigge AL, Kitch BT, **Paltiel AD**, Kuntz KM, Neumann PJ, Dockery DW, Weiss ST. FEV1 is associated with risk of asthma attacks in a pediatric population. *Journal of Allergy and Clinical Immunology* (2001) 107:61-67.
28. Ortega AN, Belanger KD, **Paltiel AD**, Horwitz SM, Bracken MB, and Leaderer BP. Use of health services by insurance status among children with asthma. *Medical Care* (2001) 39:1065-1074.
29. Kuntz KM, Kitch BT, Fuhlbrigge AL, **Paltiel AD**, Neumann PJ, and Weiss ST. A novel approach to defining the relationship between lung function and symptom status in asthma. *Journal of Clinical Epidemiology* (2002) 55:11-18.
30. Yazdanpanah Y, Goldie SJ, Weinstein MC, Losina E, Lebrun T, **Paltiel AD**, Seage GR, Leblanc G, Ajana F, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Lifetime cost of HIV-care in France during the era of highly active antiretroviral therapy, *Antiviral Therapy* (2002) 7:257-266.
31. Ortega AN, Gergen PJ, **Paltiel AD**, Bauchner H, Belanger KD, and Leaderer BP. The impact of site of care, race, and Hispanic ethnicity on medication use for childhood asthma. *Pediatrics* (2002) 109:E1.
32. Johri M, **Paltiel AD**, Goldie SJ, and Freedberg KA. State AIDS Drug Assistance Programs (ADAPs): Equity and efficiency in an era of rapidly changing treatment standards. *Medical Care* (2002) 40:429-441.
33. Goldie SJ, Kaplan JE, Losina E, Weinstein MC, **Paltiel AD**, Seage GR, Craven DE, Kimmel AD, Zhang H, Cohen CJ, Freedberg KA. Prophylaxis for HIV-related *Pneumocystis carinii* pneumonia (PCP): Using simulation modeling to inform clinical guidelines. *Archives of Internal Medicine* (2002) 162:921-928.
34. Krumholz HM, Weintraub WS, Bradford WD, Heidenreich PA, Mark DB, **Paltiel AD**. Preventive cardiology: how can we do better? Task Force #2—The Cost of Prevention: Can We Afford It? Can We Afford Not To Do It? Presented at the 33rd Bethesda Conference, Bethesda, Maryland, December 18, 2001. *Journal of the American College of Cardiology* (2002) 40:579–651.

35. Seage GR, Losina E, Goldie S, **Paltiel AD**, Kimmel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 cell counts to chronic mortality. *Journal of Acquired Immune Deficiency Syndromes* (2002) 30:421-428.
36. Walensky RP, **Paltiel AD**, and Freedberg KA. AIDS Drug Assistance Programs: Highlighting Inequities in HIV Health Care in the United States. *Clinical Infectious Diseases* (2002) 35:606-610.
37. Walensky RP, Goldie SJ, Sax PE, Weinstein MC, **Paltiel AD**, Kimmel AD, Seage GR, Losina E, Zhang H, Islam R, and Freedberg KA. Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. *Journal of Acquired Immune Deficiency Syndromes* (2002) 31:27-37.
38. Penson DF, **Paltiel AD**, Krumholz HM, and Palter S. The cost-effectiveness of treatment for varicocele-related infertility. *Journal of Urology* (2002) 168:2490-2494.
39. Yazdanpanah Y, Goldie SJ, **Paltiel AD**, Losina E, Coudeville L, Weinstein MC, Gerard MD, Kimmel AD, Zhang H, Salamon R, Mouton Y, Freedberg KA. Prevention of HIV-related Opportunistic Infections in France. A Cost-effectiveness Analysis. *Clinical Infectious Diseases* (2003) 36:86-96.
40. Akazawa M, Sindelar JL, **Paltiel AD**. Economic Costs of Influenza-Related Work Absenteeism. *Value in Health* (2003) 6:107-115.
41. Sedrakyan A, Gondek K, **Paltiel D**, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. *Chest* (2003) 123:1853-1857.
42. Sedrakyan A, Vaccarino V, **Paltiel AD**, Elefteriades JA, Mattera JA, Roumanis SA, Lin Z, and Krumholz HM. Age does not limit quality of life improvement in cardiac valve surgery. *Journal of the American College of Cardiology* (2003) 42:1208-1214.
43. Goldie SJ, **Paltiel AD**, Weinstein MC, Losina E, Seage GR, Kimmel AD, Walensky RP, Sax PE, and Freedberg KA. Projecting the cost-effectiveness of adherence interventions in persons with HIV infection. *American Journal of Medicine* (2003) 115:632-641.
44. Moy ML, Fuhlbrigge AL, Blumenschein K, Chapman RH, Zillich AJ, Kuntz KM, **Paltiel AD**, Kitch BT, Weiss ST, Neumann PJ. Association between preference based health-related quality of life and asthma severity. *Annals of Allergy, Asthma, & Immunology* (2004) 92:329-334.
45. Sedrakyan A, Herbert P, Vaccarino V, **Paltiel AD**, Elefteriades JA, Mattera JA, Lin Z, Roumanis SA, and Krumholz HM. Quality of life after aortic valve replacement with tissue and mechanical implants. *Journal of Thoracic and Cardiovascular Surgery* (2004) 128:266-272.
46. Walensky RP, **Paltiel AD**, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. Developing a therapeutic HIV vaccine: How good is good enough? *Vaccine* (2004) 28:4044-4053.
47. BT Kitch, AL Fuhlbrigge, **AD Paltiel**, KM Kuntz, PJ Neumann, DW Dockery, JP Schouten, DS Postma, and ST Weiss. FEV1 predicts risk of asthma exacerbations in long-term follow-up. *Chest* (2004) 12:1875-1882.

48. Walensky RP, Weinstein MC, Kimmel AD, Seage GR, Losina E, Sax PE, Zhang H, Smith HE, Freedberg KA, and **Paltiel AD**. Routine HIV Testing: An Economic Evaluation of Current Guidelines. *American Journal of Medicine* (2005) 118:292-300.
49. Resch S, Altice FL, and **Paltiel AD**. Cost-effectiveness of HIV screening for incarcerated pregnant women. *Journal of Acquired Immune Deficiency Syndromes* (2005) 38:163–173.
50. **Paltiel AD**, Weinstein MC, Kimmel AD, Seage GR, Losina E, Zhang H, Freedberg KA, and Walensky RP. Expanded HIV Screening in the United States – An Analysis of Cost-effectiveness. *New England Journal of Medicine* (2005) 352:586-595.
51. Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, **Paltiel AD**, Zhang H, Freedberg KA. Optimal Frequency of CD4 Cell Count and HIV RNA Monitoring Prior to Initiation of Antiretroviral Therapy in HIV-infected Patients. *Antiviral Therapy* (2005) 10:41-52.
52. Sax PE, Losina E, Weinstein MC, **Paltiel AD**, Goldie SJ, Muccio TM, Kimmel AD, Zhang H, Freedberg KA, and Walensky RP. Cost-Effectiveness of Enfuvirtide (ENF) in Treatment-Experienced Patients with Advanced HIV Disease. *Journal of Acquired Immune Deficiency Syndromes* (2005) 39:69-77.
53. Walensky RP, MC Weinstein, HE Smith, KA Freedberg, **AD Paltiel**. Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral. *Medical Decision Making* (2005) 25:321-329.
54. Goldberger Z, Elbel B, McPherson CA, **Paltiel AD**, and Lampert R. Cost Advantage of Dual versus Single Chamber Cardioverter Defibrillator Implantation. *Journal of the American College of Cardiology* (2005) 46:850-857.
55. Wild DM, Redlich CA, and **Paltiel AD**. Surveillance for Isocyanate Asthma: A Model-Based Cost-Effectiveness Analysis. *Occupational and Environmental Medicine* (2005) 62:743-9.
56. Fuhlbrigge AL, Bae SJ, Weiss ST, Kuntz KM, and **Paltiel AD**. Cost-effectiveness of Inhaled Steroids in Asthma: Impact of Effect on Bone Mineral Density. *Journal of Allergy and Clinical Immunology* (2006) 117:359-66.
57. Walensky RP, **Paltiel AD**, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, and Freedberg KA. Three million years of life saved: The survival benefits of AIDS treatment in the United States. *Journal of Infectious Diseases* (2006) 194:11-19.
58. Martin EG, Pollack HA, and **Paltiel AD**. Resource Allocation in the Ryan White CARE Act: Correlates of Title I and Title II Funding from 1998 to 2004. *Health Affairs* (2006) 25:1103-1112.
59. Fuhlbrigge AL, Weiss ST, Kuntz KM, **Paltiel AD**, and the CAMP Research Group. Forced expiratory volume in 1 second percentage improves the classification of severity among children with asthma. *Pediatrics*. (2006) 118:e347-355.
60. Walensky RP and **Paltiel AD**. Rapid HIV testing at home: Does it solve a problem or create one? *Annals of Internal Medicine* (2006) 145:459-462.

61. Gross CP, McAvay GJ, Krumholz HM, **Paltiel AD**, Bhasin D, and Tinetti ME. The Effect of Age and Chronic Illness on Life Expectancy after a Diagnosis of Colorectal Cancer: Implications for Screening. *Annals of Internal Medicine* (2006) 145:646-653.
62. **Paltiel AD**, Walensky RP, Schackman BR, Seage GR, Mercincavage LM, Weinstein MC, and Freedberg KA. Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs. *Annals of Internal Medicine* (2006) 145:797-806.
63. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, **Paltiel AD**, Katz C, Goldie SJ, and Losina E. Impact and Cost-effectiveness of an Intervention to Improve Adherence to Antiretroviral Therapy in HIV-Infected Patients. *Journal of Acquired Immune Deficiency Syndromes* (2006) 43:S113-S118.
64. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, **Paltiel AD**, Freedberg KA, and Seage GS. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. *Clinical Infectious Diseases* (2007) 44:1115-22.
65. Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, and **Paltiel AD**. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: A South African example. *Journal of Acquired Immune Deficiency Syndromes* (2007) 46:78–90.
66. Wu AC **Paltiel AD**, Kuntz KM, Weiss ST, and Fuhlbrigge AL. Cost-Effectiveness of Omalizumab in Adults with Severe Asthma: Results from the Asthma Policy Model. *Journal of Allergy and Clinical Immunology* (2007) 120:1146-52.
67. Walensky RP, Freedberg KA, Weinstein MC, and **Paltiel AD**. Cost-effectiveness of HIV Screening and Care in the United States. *Clinical Infectious Diseases* (2007) 45:S248-54.
68. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, **Paltiel AD**, and Freedberg KA. Scaling Up Antiretroviral Therapy in South Africa: The impact of speed on survival. *Journal of Infectious Diseases* (2008); 197:1324-1332.
69. Bae SJ, **Paltiel AD**, Fuhlbrigge AL, Weiss ST, and Kuntz KM. Modeling the potential impact of a prescription drug co-payment increase on the adult asthmatic Medicaid population. *Value in Health* (2008); 11(1):110-118.
70. Basu A, **Paltiel AD**, and Pollack HA. Social Costs of Robbery and the Cost-Effectiveness of Substance Abuse Treatment. *Health Economics*. (2008); 17:927-46.
71. **Paltiel AD**, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, and Walensky RP. HIV Pre-exposure prophylaxis (PrEP) in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. *Clinical Infectious Diseases* (2009); 48:806–815.
72. Losina E, Walensky RP, Kessler CL, Parastu S, Emrani PS, Reichmann WM, Wright EA, Holt HL, Solomon DH, Yelin E, **Paltiel AD**, and Katz JN. Cost-effectiveness of Total Knee Arthroplasty in the US: Patient Risk and Hospital Volume. *Archives of Internal Medicine* (2009); 169:1113-21.

73. April MD, Walensky RP, Chang Y, Pitt J, Freedberg KA, Losina E, **Paltiel AD**, Wood R. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. *Journal of Acquired Immune Deficiency Syndromes* (2009); 51:310–316.
74. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, **Paltiel AD**, Anglaret X, Weinstein MC, and Losina E. When to Start Antiretroviral Therapy in Resource-limited Settings. *Annals of Internal Medicine* 2009;151:157-66.
75. Suter LG, Fraenkel L, Losina E, Katz JN, Gomoll A, and **Paltiel AD**. Medical Decision Making in Patients with Knee Pain, Meniscal Tear and Osteoarthritis. *Arthritis Care & Research* 2009;61:1531-1538.
76. Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, Weinstein MC, Hicks PL, Aaronson WH, Moore RD, **Paltiel AD**, and Freedberg KA. Racial and Sex Disparities in Life Expectancy Losses Among HIV-infected Persons in the United States: Impact of Risk Behavior, Late Initiation and Early Discontinuation of Antiretroviral Therapy. *Clinical Infectious Diseases* 2009; 49:1570-1578.
77. Losina E, Touré H, Uhler LM, Anglaret X, **Paltiel AD**, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, and Freedberg KA. Cost-effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: a Côte d'Ivoire Appraisal. *PLoS Medicine* 2009 Oct;6(10):e1000173. PMID: 19859538.
78. **Paltiel AD** and Pollack HA. Price, Performance, and the FDA Approval Process: The Example of Home HIV Testing. *Medical Decision Making* 2010; 30:217-223.
79. Rubin JB, **Paltiel AD** and Saltzman WM. Are We Studying What Matters? Health Priorities and NIH-Funded Biomedical Engineering Research. *Annals of Biomedical Engineering* 2010;38:2237-2251.
80. Walensky RP, **Paltiel AD**, Losina E, Morris BE, Scott Rhode ER, Seage GR, and Freedberg KA. Test and Treat DC: Forecasting the Impact of a Comprehensive HIV Strategy in Washington DC. *Clinical Infectious Diseases* (2010) 51:392-400.
81. Andersson KM, Owens DK, and **Paltiel AD**. Scaling up circumcision programs in Southern Africa: The potential impact of gender disparities and changes in condom use behaviors on heterosexual HIV transmission. *AIDS and Behavior* (2010) 15:938-948. PMID: 20924783.
82. Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D, Pillonel J, Poullié AI, Scemama O, Deuffic-Burban S, Losina E, Walensky RP, Freedberg KA and **Paltiel AD**. Routine HIV screening in France: Clinical impact and cost-effectiveness. *PloS One* (2010) 5(10): e13132. PMID: 20976112.
83. Martin EG, **Paltiel AD**, Walensky RP, and Schackman BR. Expanded HIV Screening in the U.S.: What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis. *Value in Health* (2010) 13:893-902. PMCID: PMC2999642.
84. Walensky RP, Wood R, Ciaranello AL, **Paltiel AD**, Lorenzana SB, Anglaret X, Stoler A, and Freedberg KA. Scaling up the 2010 WHO HIV treatment guidelines in resource-limited settings: A model-based analysis. *PLoS Medicine* (2010) 7:e1000382. PMID: 21209794.

85. Walensky RP, Wood R, Fofana MO, Martinson NA, Losina E, April MD, Bassett IV, Morris BL, Freedberg KA, and **Paltiel AD**. The Clinical Impact and Cost-Effectiveness of Routine, Voluntary HIV Screening in South Africa. *Journal of Acquired Immune Deficiency Syndromes* (2011) Jan 1;56(1):26-35. PMID: 21068674.
86. April MD, Chiosi JJ, **Paltiel AD**, Sax PE, and Walensky RP. Projected survival gains from revising state laws requiring written opt-in consent for HIV testing. *Journal of General Internal Medicine* (2011) doi: 10.1007/s11606-011-1637-5 PMID: 21286837.
87. Losina E, Walensky RP, Gerlovin H, Reichmann WM, Kessler CL, Solomon DH, Jordan JM, Hunter DJ, Suter LG, **Paltiel AD**, and Katz JN. Impact of Obesity and Knee Osteoarthritis on Morbidity and Mortality in Older Americans. *Annals of Internal Medicine* (2011) 154:217-226. PMID: 21320937.
88. Luz PM, Vanni T, Medlock J, **Paltiel AD**, Galvani AP. Dengue vector control strategies in an urban setting: an economic modelling assessment. *Lancet* (2011) 377:1673-80. PMCID: PMC3409589.
89. Andersson KM, **Paltiel AD**, and Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. *Vaccine* (2011) 29:6107-6112. PMID: 21736912.
90. Walensky RP, Morris BL, Reichmann WM, **Paltiel AD**, Arbelaez C, Donnell-Fink L, Katz JN, and Losina EL. Resource Utilization and Cost-effectiveness of Counselor- vs. Provider-based Rapid Point-of-Care HIV Screening in the Emergency Department. *PLoS ONE* (2011) 6(10): e25575. doi:10.1371/journal.pone.0025575. PMID: 22022415.
91. Suter LG, **Paltiel AD**, Rome BN, Solomon DH, Golovaty I, Gerlovin H, Katz JN, and Losina E. Medical Device Innovation — Is “Better” Good Enough? *New England Journal of Medicine* (2011) 365:1464-6. PMID: 22010911.
92. Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, Ajana F, Melliez H, **Paltiel AD**, Freedberg KA, and Yazdanpanah Y. Newer drugs and earlier treatment: Impact on lifetime cost of care for HIV-infected adults. *AIDS* (2012) 26:45-56. PMID: 22008655.
93. Walensky RP, Park J-E, Wood R, Freedberg KA, Scott CA, Bekker L-G, Losina E, Mayer KH, Seage GR, and **Paltiel AD**. The Cost-Effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. *Clinical Infectious Diseases* (2012) 54:1504-1513. PMID: 22474224.
94. Ibuka Y, **Paltiel AD**, and Galvani AP. Impact of program scale and indirect effects on the cost-effectiveness of vaccination programs. *Medical Decision Making* (2012) 32:442-446. PMID: 22472916.
95. Roberts M, Russell LB, **Paltiel AD**, Chambers M, McEwan P, and Krahn M. Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Jointly published in *Medical Decision Making* (2012) 32:678-689; and *Value in Health* (2012) 15:804-811.

96. Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, and **Paltiel AD**. Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Jointly published in *Medical Decision Making* (2012) 32:722-732; and *Value in Health* (2012) 15:835-842.
97. **Paltiel AD** and Walensky RP. Home HIV testing: Good news but not a game changer. *Annals of Internal Medicine* (2012) 157:744-746.
98. Araz OM, Damien P, **Paltiel DA**, Burke S, van de Geijn B, Galvani A, and Meyers LA. Simulating School Closure Policies for Cost Effective Pandemic Decision Making. *BMC Public Health* (2012) 12:449.
99. Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, **Paltiel AD**, and Schackman BR. Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. *Annals of Internal Medicine* (2013) 158:84-92.
100. Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, Matheson T, Haynes LF, **Paltiel AD**, and Walensky RP. The Cost-effectiveness of Rapid HIV Testing in Substance Abuse Treatment: Results of a Randomized Trial. *Drug and Alcohol Dependence* (2013) 128:90-97. PMID: 22971593.
101. Suter LG, **Paltiel AD**, Rome BN, Solomon DH, Thornhill TS, Abrams SK, Katz JN, Losina E. Placing a Price on Medical Device Innovation: The Example of Total Knee Arthroplasty. *PLoS ONE* 8(5): e62709. doi:10.1371/journal.pone.0062709.
102. Losina E, Daigle ME, Suter LG, Hunter DJ, Solomon DH, Walensky RP, Jordan JM, Burbine SA, **Paltiel AD**, and Katz JN. Disease-Modifying Drugs for Knee Osteoarthritis: Can They Be Cost-Effective? *Osteoarthritis and Cartilage* (2013) 21:655-667.
103. Durham DP, Mbah MLN, Medlock J, Luz PM, **Paltiel AD**, Galvani AP. Dengue dynamics and vaccine cost-effectiveness in Brazil. *Vaccine* (2013) 31:3957-3961.
104. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, **Paltiel AD**, Nakamura YM, Godbole SV, et al. The Cost-Effectiveness of HIV Treatment as Prevention: Analysis of HPTN 052. *N Engl J Med* (2013) 369:1715-1725.
105. Yazdanpanah Y, Perelman J, Dilorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Kamal Mansinho K, Robine M, Park J, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, and **Paltiel AD**. Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. *PLoS ONE* (2013) 8: e84173. doi:10.1371/journal.pone.0084173.
106. Fitzpatrick MC, Hampson K, Cleaveland S, Mzimhiri I, Lankester F, Lembo T, Meyers LA, **Paltiel AD**, and Galvani AP. Cost-effectiveness of canine vaccination to prevent human rabies in rural Tanzania. *Annals of Internal Medicine* (2014) 160:91-100.
107. Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, Noubary F, **Paltiel AD**, Wood R, Walensky RP, Losina E, Bekker L-G, and Freedberg KA. Mobile HIV Screening in Cape Town, South Africa: Clinical Impact, Cost and Cost-Effectiveness. *PLoS ONE* (2014) 9: e85197. doi:10.1371/journal.pone.0085197.

108. April MD, Wood R, Berkowitz BK, **Paltiel AD**, Anglaret X, Losina E, Freedberg KA and Walensky RP. The survival benefits of Antiretroviral Therapy in South Africa. *Journal of Infectious Diseases* (2014) 209:491-9.
109. Skene KJ, **Paltiel AD**, Shim E, and Galvani AP. A marginal benefit approach for vaccinating influenza ‘superspreaders.’ *Medical Decision Making* (2014) 34:536–549.
110. Ouattara E, Ross EL, Yazdanpanah Y, Wong AY, Robine M, Losina E, Moh R, Walensky RP, Danel C, **Paltiel AD**, Eholié SP, Freedberg KA, and Anglaret X. Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: A model-based analysis in Côte d'Ivoire. *Journal of Acquired Immune Deficiency Syndromes* (2014) 66:294-302.
111. Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, **Paltiel AD**, Resch S, Freedberg KA, Peter T, and Walensky RP. The Clinical and Economic Impact of Point of Care CD4 Testing in Resource-Limited Settings. *PLoS Medicine* (2014) 11(9): e1001725. doi:10.1371/journal.pmed.1001725.
112. Sax PE, Sypek A, Berkowitz BK, Morris BL, Losina E, **Paltiel AD**, Kelly KA, Seage GR, Walensky RP, Weinstein MC, Eron J, and Freedberg KA. HIV cure strategies: How good must they be to improve on current antiretroviral therapy? *PLoS ONE* (2014) 9(11): e113031. doi:10.1371/journal.pone.0113031
113. Luz PM, Morris BL, Grinsztejn B, Freedberg KA, Veloso VG, Walensky RP, Losina E, Nakamura YN, Girouard MP, Sax PE, Struchiner CJ, and **Paltiel AD**. The cost-effectiveness of genotype testing for primary resistance in Brazil. *Journal of Acquired Immune Deficiency Syndromes* (2015) 68:152-61.
114. Losina E, **Paltiel AD**, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, and Katz JN. Lifetime medical costs of knee osteoarthritis management in the United States: Impact of extending indications for total knee arthroplasty? *Arthritis Care & Research* (2015) 67:203-15.
115. Ross EL, Weinstein MC, Schackman BR, Sax PE, **Paltiel AD**, Walensky RP, Freedberg KA and Losina E. The clinical role and cost-effectiveness of long-acting antiretroviral therapy? *Clinical Infectious Diseases* (2015) 60:1102-10.
116. Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, **Paltiel AD**, Weinstein MC, and Freedberg KA, Gebo KA, and Losina E. The Lifetime Medical Cost Savings from Preventing HIV in the United States. *Medical Care* (2015) 53:293-301.
117. Gonsalves GS, Kaplan EH, and **Paltiel AD**. Reducing Sexual Violence by Increasing the Supply of Toilets in Khayelitsha, South Africa: A Mathematical Model. *PLoS ONE* (2015) 10:e0122244.
118. Losina E, Dervan EE, **Paltiel AD**, Dong Y, Wright RJ, Spindler KP, Mandl LA, Jones MH, Marx RG, Safran-Norton CE, and Katz JN. Defining the value of future research to identify the preferred treatment of meniscal tear in the presence of knee osteoarthritis. *PLoS ONE* (2015) 10: e0130256. doi:10.1371/journal.pone.0130256.

119. **Paltiel AD**, Ingvarsson E, Lee DKK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC. Demographic and clinical features of inclusion body myositis in North America. *Muscle & Nerve* (2015) 52:527-533.
120. Pei PP, Weinstein MC, Li XC, Hughes MD, **Paltiel AD**, Hou T, Parker RA, Gaynes MR, Sax PE, Freedberg KA, Schackman BR, and Walensky RP. Prioritizing HIV Comparative Effectiveness Trials Based on Value of Information: Generic vs. Brand-Name ART in the US. *HIV Clinical Trials* (2015) 16:207-18.
121. Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Yelin E, **Paltiel AD**, and Losina E. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. *Osteoarthritis and Cartilage* (2016) 24:409-18.
122. Luz PM, Girouard MP, Grinsztejn B, Freedberg KA, Veloso VG, Losina E, Nakamura YN, Struchiner CJ, Maclean RL, Parker RA, **Paltiel AD**, and Walensky RP. Survival Benefits of Antiretroviral Therapy in Brazil. *Journal of the International AIDS Society* (2016) 19:20623.
123. Girouard MP, Sax PE, Parker RA, Taiwo B, Freedberg KA, Gulick RM, Weinstein MC, **Paltiel AD**, and Walensky RP. The cost-effectiveness and budget impact of two-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. *Clinical Infectious Diseases* (2016) 62:784-91.
124. Losina E, Griffin M, Collins J, Hunter DJ, Jordan JM, Yelin E, **Paltiel AD**, and Katz JN. Model-based evaluation of cost-effectiveness of Nerve Growth Factor Inhibitors in Knee Osteoarthritis: Impact of drug cost, toxicity, and means of administration. *Osteoarthritis & Cartilage* (2016) 24:776-85.
125. Walensky RP, Jacobsen MM, Bekker LG, Parker RA, Wood R, Resch SC, Horstman NK, Freedberg KA, **Paltiel AD**. The potential clinical and economic value of long-acting pre-exposure prophylaxis (LA-PrEP) for HIV Infection in high-risk South African women. *Journal of Infectious Diseases* (2016) 213:1523-31.
126. Ouattara EN, Robine M, Eholié SP, MacLean RL, Moh R, Losina E, Gabillard D, **Paltiel AD**, Danel C, Walensky RP, Anglaret X, Freedberg KA. Laboratory monitoring of antiretroviral therapy for HIV infection: Cost-effectiveness and budget impact of current and novel strategies. *Clinical Infectious Diseases* (2016) 62:1454-62.
127. Walensky RP, Borre ED, Bekker LG, Resch SC, Hyle EP, Wood R, Weinstein MC, Ciaranello AL, Freedberg KA, and **Paltiel AD**. The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. *Annals of Internal Medicine* (2016) 165:325-33.
128. Bilinski AM, Fitzpatrick MC, Rupprecht CE, **Paltiel AD**, Galvani AP. Optimal frequency of rabies vaccination campaigns in sub-Saharan Africa. *Proceedings of the Royal Society B* (2016) 283: 20161211.
129. Reddy KP, Parker RA, Losina E, Baggett TP, **Paltiel AD**, Rigotti NA, Weinstein MC, Freedberg KA, and Walensky RP. The Impact of Cigarette Smoking and Smoking Cessation on Life

Expectancy among People with HIV: A US-Based Modeling Study. *Journal of Infectious Diseases* (2016) 214: 1672-1681.

130. Gilbert JA, Shenoi SV, Moll AP, Friedland GH, **Paltiel AD**, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. *PLoS ONE* (2016) 11:e0165614. doi: 10.1371/journal.pone.0165614.
131. Walensky RP, Horn T, and **Paltiel AD**. The epi-TAF for Tenofovir? *Clinical Infectious Diseases* (2016) 62:915-918.
132. Smith, S. R., Katz, J. N., Collins, J. E., Solomon, D. H., Jordan, J. M., Suter, L. G., Yelin, E. H., **David Paltiel, A.** and Losina, E. Cost-Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. *Arthritis Care & Research* (2017) 69: 234–242. doi:10.1002/acr.22916
133. **Paltiel AD**, Zheng A, Weinstein MC, Gaynes MR, Wood R, Freedberg KA, Sax PE, and Walensky RP. Setting performance standards for a cost-effective HIV cure strategy in South Africa. *Open Forum Infectious Diseases* (2017) 4:ofx081. doi:10.1093/ofid/ofx081.
134. Antillón M, Bilcke J, **Paltiel AD**, and Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. *Vaccine* (2017) 35:3506-3514. doi: 10.1016/j.vaccine.2017.05.001.
135. Gonsalves GS, **Paltiel AD**, Cleary PD, Gill MJ, Kitahata, MM, Rebeiro PF, Silverberg MJ, Horberg M, Abraham AG, Althoff KN, Moore R, Bosch RJ, Hall HI, and Kaplan EH. A Flow-Based Model of the HIV Care Continuum in the United States. *Journal of Acquired Immune Deficiency Syndromes* (2017) 75:548-553. doi: 10.1097/QAI.0000000000001429.
136. Gonsalves GS, Crawford FW, Cleary PD, Kaplan EH, and **Paltiel AD**. An Adaptive Approach to Locating Mobile HIV Testing Services. *Medical Decision Making* (2018) 38:262-272. doi:10.1177/0272989X17716431
137. Walensky RP, Borre ED, Bekker LG, Anglaret X, Hyle EP, Gonsalves GS, Wood R, Eholié SP, Weinstein MC, Freedberg KA, and **Paltiel AD**. Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. *Annals of Internal Medicine* (2017) 167:618-629. doi:10.7326/M17-1358.
138. Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, **Paltiel AD**, Losina E, Weinstein MC, Freedberg KA, and Walensky RP. Lung Cancer Mortality Among People Living with HIV in the U.S.: a Model-Based Analysis. *JAMA Internal Medicine* (2017) 177:1613-1621. doi:10.1001/jamainternmed.2017.4349.
139. Borre ED, Hyle EP, **Paltiel AD**, Neilan AM, Sax PE, Freedberg KA, Weinstein MC, Walensky RP. The clinical and economic impact of attaining National HIV/AIDS Strategy treatment targets in the US. *Journal of Infectious Diseases* (2017) 216:798-807. doi:10.1093/infdis/jix349.
140. Zheng A, Kumarasamy N, Huang M, **Paltiel AD**, Mayer KH, Rewari BB, Walensky RP, and Freedberg KA. The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as

first-line treatment of HIV infection in India. *Journal of the International AIDS Society* (2018) 21(3):e25085. doi: 10.1002/jia2.25085.

141. Losina E, Usiskin IM, Smith SR, Sullivan JK, Smith KC, Hunter DJ, Messier SP, **Paltiel AD**, and Katz JN. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: A model-based evaluation. *Osteoarthritis and Cartilage* (2018) 26:641-650.
142. Luz PM, Osher B, Grinsztejn B, Maclean RL, Losina E, Struchiner CJ, Parker RA, Freedberg KA, Mesquita F, Walensky RP, Veloso VG, and **Paltiel AD**. The cost-effectiveness of HIV pre-exposure prophylaxis in high-risk men who have sex with men and transgender women in Brazil *Journal of the International AIDS Society* (2018) 21(3):e25096. doi: 10.1002/jia2.25096.
143. Gonsalves GS, Copple JT, Johnson T, **Paltiel AD**, Warren JL. Bayesian Adaptive Algorithms for Locating HIV Mobile Testing Services. *BMC Medicine* (2018) 16:155.
144. Smith, KC, **Paltiel AD**, Yang HY, Collins JN, Katz, JN, and Losina E. Cost-Effectiveness of Health Coaching and Financial Incentives to Promote Physical Activity after Total Knee Replacement. *Osteoarthritis and Cartilage* (2018) 26:1495-1505.
145. Lee DJ, Kumarasamy N, Resch SC, Sivaramakrishnan GN, Mayer KH, Tripathy S, **Paltiel AD**, Freedberg KA, and Reddy KP. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: cost-effectiveness analysis for India's public sector. *PLoS ONE* (2019) 14(7): e0218890. <https://doi.org/10.1371/journal.pone.0218890>.
146. Bilcke J, Antillón M, Pieters Z, Kuylen E, Abboud L, Neuzil KM, Pollard AJ, **Paltiel AD**, and Pitzer VE. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study. *Lancet Infectious Diseases* (2019) 19:728-739.
147. Losina E, Smith, KC, **Paltiel AD**, Collins JN, Suter LG, Hunter DJ, Katz, JN, and Messier SP. Cost-Effectiveness of Diet and Exercise for Overweight and Obese Knee Osteoarthritis Patients. *Arthritis Care & Research* (2019) 71:855-864.
148. Ouattara EN, MacLean RL, Danel C, Borre E, Gabillard D, Huang M, **Paltiel AD**, Eholié SP, Walensky RP, Anglaret X, Freedberg KA. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: a model-based analysis. *PLoS ONE* (2019) 14:e0219068.
149. Kunst NR, Alarid-Escudero F, **Paltiel AD**, Wang S. A value of information analysis of research on the 21-gene assay for breast cancer management. *Value in Health* (2019) 22:1102-1110.
150. Losina E, Silva GS, Smith, KC, Collins JN, Hunter DJ, Shrestha S, Messier SP, Yelin EH, Suter LG, **Paltiel AD**, and Katz, JN. Quality-Adjusted Life-Years Lost Due to Physical Inactivity in the United States Osteoarthritis Population. *Arthritis Care & Research* (2020) 72:1349:1357. doi: 10.1002/acr.24035.
151. Smith, KC, Losina E, Messier SP, Hunter DJ, Chen AT, Katz JN, and **Paltiel AD**. Budget Impact of Funding an Intensive Diet and Exercise Program for Overweight and Obese Knee Osteoarthritis Patients. *ACR Open Rheumatology* (2020) 2:26-36.

152. Kazemian P, Costantini S, Kumarasamy N, **Paltiel AD**, Mayer KH, Chandhiok N, Walensky RP, and Freedberg KA. The Cost-effectiveness of HIV Pre-exposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India. *Clinical Infectious Diseases* (2020) 70:633-642.
153. Morozova O, Crawford FW, Cohen T, **Paltiel AD**, Altice FL. Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis. *Addiction* (2020) 115:437-450.
154. Reddy KP, Bulteel AJB, Levy DE, Torola P, Hyle EP, Hou T, Osher B, Yu L, Shebl FM, **Paltiel AD**, Freedberg KA, Weinstein MC, Rigotti NA, and Walensky RP. Novel microsimulation model of tobacco use behaviors and outcomes: calibration and validation in a US population. *BMJ Open* (2020) 10:e032579. doi: 10.1136/bmjopen-2019-032579
155. Walensky RP, Horn T, McCann NC, Freedberg KA and **Paltiel AD**. Comparative pricing of branded tenofovir alafenamide/emtricitabine relative to generic tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: A cost-effectiveness analysis. *Annals of Internal Medicine* (2020) 172:583-590. <https://doi.org/10.7326/M19-3478> .
156. Weinstein MC, Freedberg KA, Hyle EP, and **Paltiel AD**. Waiting for Certainty on Covid-19 Antibody Tests — At What Cost? *New England Journal of Medicine* (2020) 382 <https://doi.org/10.1056/NEJMp2017739> .
157. **Paltiel AD**, Zheng A, Walensky RP. Assessment of SARS-CoV-2 Screening Strategies to Permit the Safe Reopening of College Campuses in the United States. *JAMA Network Open*. 2020;3(7):e2016818. <https://doi.org/10.1001/jamanetworkopen.2020.16818> .
158. Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, **Paltiel AD**, Weinstein MC, Wilson CM, and Ciaranello AL. Cost-effectiveness of frequent HIV screening among high-risk young men who have sex with men in the United States. *Clinical Infectious Diseases* (2020) Jul 30:ciaa1061. <https://doi.org/10.1093/cid/ciaa1061> . PMID: 32730625.
159. Castry M, Cousien A, Supervie V, Velter A, Ghosn J, **Paltiel AD**, Yazdanpanah Y, Deufflic-Burban S. Impact of test-and-treat and risk reduction strategies on HCV transmission among MSM living with HIV in France: a modeling approach. *Gut* (2020) Oct 27; <https://doi.org/10.1136/gutjnl-2020-321744> .
160. **Paltiel AD**, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes of a COVID-19 Vaccine: Implementation over Efficacy. *Health Affairs* (2021) 40: 42-52. <https://doi.org/10.1377/hlthaff.2020.02054>
161. **Paltiel AD**, Zheng A, and Schwartz JL. Speed vs. Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. *Annals of Internal Medicine* (2021) <https://doi.org/10.7326/M20-7866>
162. Yaesoubi R, Havumaki J, Chitwood MH, Menzies NA, Gonsalves G, Salomon J, **Paltiel AD**, and Cohen T. Adaptive policies for use of physical distancing interventions during the COVID-19 pandemic. *Medical Decision Making* (2021) <https://doi.org/10.1177%2F0272989X21990371>

163. **Paltiel AD**, Zheng A, and Sax PE. Clinical and Economic Impact of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. *Annals of Internal Medicine* (2021) 174(6):803-810. <https://doi.org/10.7326/M21-0510>.
164. Gonsalves GS, **Paltiel AD**, Thornhill T, Iloglu S, DeMaria A, Cranston K, Kleven RM, Walensky RP, and Warren JL. The Dynamics of Infectious Diseases Associated with Injection Drug Use in Lawrence and Lowell, Massachusetts. *Open Forum Infectious Diseases* (2021) <https://doi.org/10.1093/ofid/ofab128>.
165. Chen AT, Bronshter CI, Stanley EE, **Paltiel AD**, Sullivan JK, Collins JN, Neogi T, Katz, JN, and Losina E. The value of total knee replacements (TKR) in knee OA patients with BMI ≥ 40 kg/m²: A cost-effectiveness analysis. *Annals of Internal Medicine* (2021) <https://doi.org/10.7326/M20-4722>.
166. Gonsalves GS, Copple JT, **Paltiel AD**, Fenichel EP, Bayham J, Abraham M, Kline D, Malloy S, Rayo M, Zhang N, Faulkner D, Morey D, Wu F, Thornhill T, Iloglu S, and Warren JL. Maximizing the Efficiency of Active Case-Finding for SARS-CoV-2 Using Bandit Algorithms. *Medical Decision Making* (2021) Nov;41(8):970-977. <https://doi.org/10.1177/0272989X211021603>. PMID: 34120510
167. **Paltiel AD** and Schwartz JL. Assessing COVID prevention strategies to permit the safe opening of residential colleges in fall 2021. *Annals of Internal Medicine* (2021) <https://doi.org/10.7326/M21-2965> Epub ahead of print. PMID: 34461034.
168. Gonsalves GS, Salomon JA, Thornhill T, **Paltiel AD**. Adventures in COVID-19 Policy Modeling: Education Edition. *Current HIV/AIDS Reports* (2021) <https://doi.org/10.1007/s11904-021-00592-9> Epub ahead of print. PMID: 34826066; PMCID: PMC8617548.
169. Schultes O, Clarke V, **Paltiel AD**, Cartter M, Sosa L, Crawford FW. COVID-19 Testing and Case Rates and Social Contact Among Residential College Students in Connecticut During the 2020-2021 Academic Year. *JAMA Network Open*. 2021;4(12):e2140602. <https://doi.org/10.1001/jamanetworkopen.2021.40602>.
170. Yaesoubi R, Mahin M, Martin G, **Paltiel AD** Sharifi M. Reducing the Prevalence of Alcohol-Exposed Pregnancies in the United States: A Simulation Modeling Study. *Medical Decision Making*. 2022;42:217-227. <https://doi.org/10.1177/0272989X211023203>. PMID: 34166146.
171. Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, **Paltiel AD**, and Walensky RP. Cost-effectiveness of long-acting injectable HIV pre-exposure prophylaxis in the United States. *Annals of Internal Medicine* (2022). <https://doi.org/10.7326/M21-1548>.
172. Roy B, Zubair A, Petschke K, O'Connor KC, **Paltiel AD**, Nowak RJ. Reliability of patient self-reports to clinician-assigned functional scores of Inclusion Body Myositis. *Journal of the Neurological Sciences* (2022). <https://doi.org/10.1016/j.jns.2022.120228>
173. Huizinga JL, Stanley EE, Sullivan JK, Song S, Hunter DJ, **Paltiel AD**, Neogi T, Edwards RR, Katz, JN, and Losina E. Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients

in the United States. *Arthritis Care & Research* (2022) 74(8):1349-1358.
<https://doi.org/10.1002/acr.24581>

174. Williams EE, Katz JN, Leifer VP, Collins JE, Neogi T, Suter LG, Farid A, **Paltiel AD**, and Losina E. Cost-effectiveness of Arthroscopic Partial Meniscectomy and Physical Therapy for Degenerative Meniscal Tear. *ACR Open Rheumatology* (2022) 4: 853-862.
<https://doi.org/10.1002/acr2.11480>
175. Savinkina A, Bilinski A, Fitzpatrick MC, **Paltiel AD**, Rizvi Z, Salomon JA, Thornhill T, and Gonsalves GS. Estimating deaths averted and cost per life saved by scaling-up mRNA COVID-19 vaccination in low and lower-middle income countries in the COVID-19 Omicron variant era: a modelling study. *BMJ Open* (2022) 12:e061752. <https://doi.org/10.1136/bmjopen-2022-061752>
176. Kostic AM, Leifer VP, Selzer F, Hunter DJ, **Paltiel AD**, Chen AF, Robinson MK, Neogi T, Collins JE, Messier SP, Edwards RR, Katz JN, and Losina E. The Cost-Effectiveness of Weight Loss Interventions Prior to Total Knee Replacement for Patients with Class III Obesity. *Arthritis Care & Research* (2022) <https://doi.org/10.1002/acr.25044>.
177. Savinkina A, Ross JS, **Paltiel AD**, and Gonsalves G. Population-level strategies for nirmatrelvir/ritonavir prescribing - a cost-effectiveness analysis. *Open Forum Infectious Diseases* (2022) <https://doi.org/10.1093/ofid/ofac637>.
178. Benson GP, Rogers A, Leifer VP, Edwards RR, Neogi T, Kostic A, **Paltiel AD**, Collins JE, Hunter DJ, Katz JN, and Losina E. Does gabapentin provide benefit for patients with knee OA? A benefit-harm and cost-effectiveness analysis. *Osteoarthritis and Cartilage* (2022) <https://doi.org/10.1016/j.joca.2022.07.013>.
179. Castry M, Cousien A, Champenois K, Supervie V, Velter A, Ghosn J, Yazdanpanah Y, **Paltiel AD**, and Deuffic-Burban S. Cost-effectiveness of HCV test-and-treat and risk reduction strategies among men who have sex with men living with HIV in France. *Journal of the International AIDS Society* (2022) <https://doi.org/10.1002/jia2.26035>
180. Savinkina A, Chitwood M, Kwon J, Pitzer VE, Gonsalves G, and **Paltiel AD**. Planning for Mpox on a College Campus: A Model-Based Decision-Support Tool. *Annals of Internal Medicine* (2023) <https://doi.org/10.7326/M22-2734>.
181. Gonsalves GS, **Paltiel AD**, Thornhill T, DeMaria A, Cranston K, Klevens RM, and Warren JL. Patterns of Infectious Disease Associated with Injection Drug Use in Massachusetts. *Clinical Infectious Diseases* (2023) <https://doi.org/10.1093/cid/ciad073>.
182. Phillips MT, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil KM, Gordon MA, Thindwa D, **Paltiel AD**, Yaesoubi R, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. *BMC Infect Dis*. 2023 Mar 8;23(1):143. <https://doi.org/10.1186/s12879-023-08105-2>.
183. **Paltiel AD**, Ahmed AR, Jin EY, McNamara M, Freedberg KA, Gonsalves GS, and Neilan AM. Increased HIV transmissions with reduced insurance coverage for HIV pre-exposure

prophylaxis: Potential consequences of Braidwood Management v. Becerra. *Open Forum Infectious Diseases* (2023) <https://doi.org/10.1093/ofid/ofad139>.

Bibliography: Papers in press

Pei PP, Fitzmaurice KP, Le MH, Panella C, Jones ML, Pandya A, Horsburgh CR, Freedberg KA, Weinstein MC, **Paltiel AD**, and Reddy KP. The value-of-information and value-of-implementation from clinical trials of diagnostic tests for HIV-associated tuberculosis: a modeling analysis. *MDM Policy & Practice* (in press).

Bibliography: Books

National Academy of Medicine Committee on Pain Management and Regulatory Strategies to Address Prescription Opioid Abuse. *Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use*. Washington, DC: National Academy Press, (2017).

Institute of Medicine Committee on Review of Priorities in the National Vaccine Plan. *Priorities for the National Vaccine Plan*. Washington, DC: National Academy Press, (2010).

Institute of Medicine Committee for the Evaluation of the President's Emergency Plan for AIDS Relief (PEPFAR) Implementation. *PEPFAR Implementation: Progress and Promise*. Washington, DC: National Academy Press, (2007).

Institute of Medicine Committee on the Ryan White CARE Act: Data for Resource Allocation, Planning and Evaluation. *Measuring What Matters: Allocation, Planning, and Quality Assessment for the Ryan White CARE Act*. Washington, DC: National Academy Press, (2004).

Bibliography: Letters

Walensky RP, Horn T, McCann NC, Freedberg KA and **Paltiel AD**. Comparative pricing of branded tenofovir alafenamide/emtricitabine relative to generic tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis. *Annals of Internal Medicine* (2020) 173:507-508. <https://doi.org/10.7326/L20-0693>.

Luz PM, Grinsztejn B, Veloso VG, and **Paltiel AD**. Yes, genotype testing is cost-effective for primary resistance in Brazil. *J Acquir Immune Defic Syndr* 2015 Nov 16.

Paltiel AD, Walensky RP, Freedberg KA. Misinterpretation of HIV Preexposure Prophylaxis Findings. *Clinical Infectious Diseases* 2014 Apr 12;59(1):139-141.

Yazdanpanah Y, Walensky RP, Rozenbaum W, Yeni P, **Paltiel AD**. What is a modest public health impact? *Archives of Internal Medicine* 2012 Mar 26;172(6):521-2. PMID: 22450944.

Kahn JG, Pinkerton SD, **Paltiel AD**. Postexposure prophylaxis following HIV exposure. *JAMA* (1999) 281:1269-70.

Bibliography: Editorials, invited commentaries, reviews, and book chapters

(* indicates peer-reviewed manuscripts)

* Kim DD, **Paltiel AD**, and Neumann PJ. Vaccines are not cost-effective, vaccinations are. *Health Affairs Forefront* February 4, 2022. doi: 10.1377/forefront.20220202.717744

Paltiel AD. Responding to SARS-CoV-2 on College Campuses—Only Beginning to Understand What Works and Why. *JAMA Network Open* 2021;4(12):e2138904. doi:10.1001/jamanetworkopen.2021.38904

Schwartz JL, **Paltiel AD**, Walensky RP and Zheng A. America's health depends on how fast and well we distribute the COVID vaccine. *USA Today* Nov 19, 2020. <https://www.usatoday.com/story/opinion/2020/11/19/covid-19-vaccine-distribution-not-just-development-necessary-column/6333001002/>

Paltiel AD and Walensky RP. No Norman Rockwell Thanksgiving. *Boston Globe*, October 31, 2020.

* Walensky RP and **Paltiel AD**. Screening To Prevent SARS-Cov-2 Outbreaks: Saliva-Based Antigen Testing Is Better Than The PCR Swab. *Health Affairs Blog* (now *Health Affairs Forefront*), September 11, 2020. DOI: 10.1377/hblog20200909.430047.

* Marcus JL, **Paltiel AD**, and Walensky RP. Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out. *Clin Infect Dis* 2020 Feb 25:ciz1236. doi: 10.1093/cid/ciz1236. Online ahead of print.

* Walensky RP and **Paltiel AD**. PrEP School: A Field Manual For The Battle Over HIV Prevention Drug Pricing. *Health Affairs Blog* (now *Health Affairs Forefront*), August 29, 2019. DOI: 10.1377/hblog20190826.11005

* Walensky RP and **Paltiel AD**. New USPSTF Guidelines for HIV Screening and Preexposure Prophylaxis (PrEP): Straight A's. *JAMA Network Open*. 2019;2(6):e195042. doi:10.1001/jamanetworkopen.2019.5042

* **Paltiel AD**, KM Kuntz, ST Weiss, AL Fuhlbrigge. An Asthma Policy Model. In F Sainfort, M Brandeau, and W Pierskalla (eds.), *Handbook of OR/MS Applications in Health Care*. Boston: Kluwer Academic Publishers (2004).

Paltiel AD. A clinician's guide to economic evaluation. In S Rimar (ed.) *The Yale Management Guide for Physicians*. New York: John Wiley & Sons (2001).

- * Kitch B, **Paltiel AD**, Kuntz KM, Neumann PJ, and Weiss ST. Development of a pharmacoeconomic policy model for asthma. In KB Weiss, AS Buist, and SD Sullivan (eds.), *Asthma's Impact on Society*. New York: Marcel Dekker, Inc. (1999).
- * **Paltiel AD** and Stinnett AA. "Resource allocation and the funding of HIV prevention." In DR Holtgrave (ed.), *Handbook of HIV Prevention Policy Analysis*. New York: Plenum Press (1998).
- Paltiel AD**. "Organ allocation and the secretary problem." (Editorial) *Medical Decision Making* (1997) 17: 231-232.
- * **Paltiel AD** and Stinnett AA. "AIDS." In: B Spilker (ed.), *Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edition*. New York: Raven Press (1996).
- * Stinnett AA and **Paltiel AD**. "Economic analysis and AIDS clinical research." In: DM Finkelstein and DA Schoenfeld (eds.), *AIDS Clinical Trials*. New York: Wiley-Liss, (1995).
- * **Paltiel AD**. "Timing is of the essence: matching AIDS policy to the epidemic life cycle." In EH Kaplan and ML Brandeau, eds. *Modeling the AIDS Epidemic*, New York: Raven Press, (1994).
- Paltiel AD**: "Inventing AIDS" by Cindy Patton (Review). *Policy Sciences* (1992) 25:77-79.
- * Kaplan EH, Cramton PC, **Paltiel AD**. Nonrandom mixing models of HIV transmission. In C. Castillo-Chavez (ed.), *Mathematical and Statistical Approaches to AIDS Epidemiology*. Berlin: Springer-Verlag 83 (1989).